![](https://france-biotech.fr/wp-content/uploads/2022/06/TRANGENE.png)
![](https://france-biotech.fr/wp-content/uploads/2022/06/TRANGENE.png)
Transgene Presented Additional Phase I Data
![](https://france-biotech.fr/wp-content/uploads/2022/05/ENTEROME.png)
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
![](https://france-biotech.fr/wp-content/uploads/2022/06/TRANGENE.png)
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
![](https://france-biotech.fr/wp-content/uploads/2022/03/IMMUTEP-BLANC.jpg)
Immutep reports positive Overall Response Rate
in its Phase II clinical trial in 1st line NSCLC for PD-L1 all-comers
![](https://france-biotech.fr/wp-content/uploads/2022/05/ose.jpg)
Présentation de quatre posters au congrès annuel de l’ASCO 2022
![](https://france-biotech.fr/wp-content/uploads/2022/06/hemerion.png)